IOVANCE BIOTHERAPEUTICS, INC. (IOVA) AI Stock Summary

Snapshot

Iovance is a commercial biotech growing revenue fast, hitting $263.5M in FY 2025 (up 61%). The gross margin is extremely healthy at 97%, but the company is not profitable, reporting a $391M net loss. It burns about $336M in free cash flow annually, which leaves a tight cash runway of roughly 6 months on the current $297M cash balance. Shareholders have also faced 23% dilution over the last year as the company funds this growth.

What's Happening Right Now

• Wed 10th Jun '26 · Regulatory approval: Australian regulators granted marketing authorization for Amtagvi, marking the drug's third global approval. Shareholders also voted to increase authorized shares from 500 million to 650 million.
• Mon 1st Jun '26 · Pipeline update: The FDA cleared the IND application for IOV-5001, a next-generation therapy targeting advanced colorectal and breast cancers, with trials set to begin in late 2026.
• Fri 8th May '26 · Earnings miss: The stock dropped 13% after the company reported Q1 sales that fell short of analyst estimates, despite earnings matching expectations.
• Thu 7th May '26 · Guidance: Management raised full-year 2026 revenue guidance to $350 million to $370 million, citing record demand for Amtagvi and Proleukin.

Ownership

Institutions hold 55.8% of shares, while insiders own just 0.3%.

Bottom Line

Iovance is successfully ramping up sales of its melanoma drug, with revenue up 61% and a new approval in Australia. However, the business burns cash faster than it sells product, leaving a runway of only about 6 months. The company recently approved increasing its authorized share count, strongly signaling that a capital raise is likely coming to bridge the gap.